This is a purely administrative correction with no change in stake or intent. Monitor for any future conversion to a 13D if Blue Owl's investment approach shifts, but no immediate action warranted.
IMA drugs
IMA drug pipeline →Price Chart
How similar events traded
Executive Summary
Blue Owl Capital Holdings LP filed an amended Schedule 13G disclosing beneficial ownership of 1,135,081 shares of ImageneBio (9.11% of shares outstanding as of October 31, 2026). The filing corrects an inadvertent omission of 217,389 shares acquired in a private placement at the IPO that were not reported in prior filings; the stake level is unchanged from the previously reported position. This is a routine administrative amendment with no change in investment intent or position size.
Key Financial Metrics
Key Facts
- Blue Owl Capital Holdings LP reports 1,135,081 shares (9.11%) of ImageneBio as of September 30, 2026
- Percentage based on 12,456,281 shares outstanding as of October 31, 2026 per the issuer's 10-Q
- Amendment corrects omission of 217,389 shares acquired in a private placement at the IPO, inadvertently left out of the initial 13G and first amendment
- No change in actual position size or investment intent; passive filer under Rule 13d-1(b)
Financial Impact
No material financial impact; administrative correction only
Risk Factors
- None from this filing; the correction resolves a prior reporting omission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001140361-26-043771 |
| Document: 0001140361-26-043771-index.html | 0001140361-26-043771 |
| Document: 0001140361-26-043771.txt | 0001140361-26-043771 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers